Maximus Review
✓ Updated September 2026
By the TelehealthIndex Editorial Team · How we score Not Recommended · #10 in Men's Health (ED & TRT)
By the TelehealthIndex Editorial Team · Advertising Disclosure: TelehealthIndex is reader-supported. If you sign up with a
provider through links on this page, we may earn a commission at no extra cost to you.
Commissions never influence our scores or rankings — several of our top-rated providers pay
us nothing. How we score → · Full disclosure →
Caution: unresolved FDA warning letter. This provider stays at its computed rank; its score is capped under
our methodology and it is not recommended while the matter is open.
39.3/100
Maximus score
Not Recommended · #10 in Men's Health (ED & TRT) · Data as of September 2026
Clinical credibilityWeak
Regulatory & safety recordSerious deductions
Transparency & trustMixed
Access & coverageLimited
Customer experienceMixed
Value & pricingMixed
Pillar ratings are qualitative summaries of our internal rubric; we do not publish the
point weights. Read the full methodology →
TelehealthIndex scores and rankings are editorial opinions resulting from our selection, weighting, and interpretation of the factors described in our methodology.
What it is
Compounded-first hormone products (enclomiphene, oral testosterone replacement therapy (TRT)+); async-heavy model; LegitScript-certified but BBB F.
Strengths
Considerations
- FDA warning letter MARCS-CMS 730095 (issued 06/08/2026, no close-out) cites maximustribe.com for false or misleading claims on compounded semaglutide and tirzepatide, including clinically-studied and FDA-approved-pharmacy representations - Caution gate applies
- Flagship products are non-FDA-approved compounded drugs - squarely in FDA's June 2026 guidance zone
- Async prescribing posture sits uneasily with DEA audio-video requirement for Schedule III testosterone
- Self-published research marketed as validation; BBB F
Note: this provider offers compounded medications for one or more services.
Compounded medications are not FDA-approved.
Founded2021
OwnershipPrivate (VC-backed)
AvailabilityNot disclosed
InsuranceNo
Money-back guaranteeNot advertised
Pricing$99.99-149.99/mo plans; ~$99 labs separate
Visit Maximus
We may earn a commission — disclosure.
Alternatives to consider
Where Maximus ranks
Compare Maximus
Sources
- FDA Warning Letters database (locate the specific record) — a find-the-record pointer, not the specific filing.
Every regulatory claim on this page is cited to its primary source (or the issuing agency's database). Verified against the cited document; see our Editorial Policy.
Data as of September 7, 2026. Scores are editorial opinions reflecting documented business practices, transparency, pricing, access, and nonclinical consumer-service factors — not clinical quality or outcomes. Found an error? Report it →